Despite recent therapeutic improvements, the prognosis for patients suffering from Sé zary syndrome (SS), a disseminated form of cutaneous T-cell lymphomas, is still poor. We identified bi-and monoallelic deletions of the tumor necrosis factor-ainduced protein 3 gene (TNFAIP3; A20) in a high proportion of SS patients as well as biallelic A20 deletion in the SS-derived cell line SeAx. Furthermore, we demonstrate that inhibition of A20 activates the NF-jB pathway thereby increasing the proliferation of normal T lymphocytes. On the other hand, the reconstitution of A20 expression slowed down the cell cycle in SeAx cells. Recently A20 inactivation has been reported in various B-cell lymphomas. In this study, we show that A20 is also a putative tumor suppressor in the T-cell malignancyFSS.
Introduction
Primary cutaneous T-cell lymphomas (CTCL) are characterized by clonally proliferating CD4 positive cells localized in the skin. 1 The Sézary syndrome (SS), an aggressive variant of CTCL, is typically characterized by erythroderma, generalized lymphadenopathy and circulating atypical T-cells with cerebriform nuclei, so-called Sézary cells. Despite recent therapeutic improvements, the prognosis of patients with SS is still poor. To establish more specific and targeted therapies, a better understanding of the underlying molecular mechanisms driving the aberrant proliferation is required. SS is characterized by unique chromosomal abnormalities, 2 however, which of the genetic alterations correspond to primary changes and contribute to disease initiation and which are secondary events, has not been clarified yet. Recent studies, employing high density comparative genomic hybridization (CGH) supported by array based transcriptional analysis revealed recurrent chromosomal gains and losses potentially relevant for the disease onset. 1 Particularly interesting is the NF-kB signaling pathway, as its constitutive activation has been identified as a key feature in CTCL, including SS. 1, 3 Recently, one of the negative regulators of this signaling pathway, the tumor necrosis factor-a-induced protein 3 (TNFAIP3; A20), attracted particular attention. A20 has initially been identified as a TNF-induced gene in human umbilical vein endothelial cells. 4, 5 Its inhibitory effect on NF-kB is based on the co-operative activity of two ubiquitin-editing domains. 6, 7 This function of A20 has been recognized for a number of substrates involved in transmission of signals from cell surface receptors to NF-kB. Well known examples are the receptor-interacting protein 1 (RIP1), [8] [9] [10] the TNF receptor-associated factor 6 (TRAF6) 9, 11 and the I-kB kinase (IKK). 9, 12 Moreover, A20 was shown to adjust NF-kB and MAP Kinase signaling pathways as well as TNF-a-induced cell death by cooperation with the E3 ubiquitin ligases Itch and RNF11 and the adaptor proteins TAX1BP1 and ABIN-1. 5, 9, 13 As a transcriptional target of NF-kB, A20 is a potent executor of a negative feedback loop mechanism leading to termination of NF-kB signaling. 14, 15 Knock-out mice deficient for A20 fail to regulate TNF-ainduced NF-kB and cell death responses and die premature because of severe inflammation and cachexia. 9 Although it was proven that these symptoms do not result from an extensive adaptive immune response, 16 abnormally high numbers of lymphocytes were observed in these animals. This indicates that apart from the control of an innate immune response, A20 is further involved in homeostasis of lymphoid cells. The fact that T lymphocytes represent the only cells in which A20 expression does not require any induction, 5 further underlines its significant role in T-cell control.
NF-kB has been reported as constitutively activated in CTCL cell lines as well as in peripheral blood lymphocytes of SS patients. 3 This prompted us to perform a detailed analysis of the genomic region encoding A20 in blood samples of SS patients to determine its potential role in the observed permanent NF-kB activity. Using high-resolution comparative genomic array hybridization, we found bi-and monoallelic A20 deletions in a high proportion of SS samples. In addition, we demonstrated in a SS-derived cell line that restoration of A20 slows down cell cycle progression, and on the other hand knockdown of A20 in normal T cells promoted proliferation. The results presented here suggest A20 as a putative tumor suppressor in this subset of CTCL.
Materials and methods

Clinical samples
Thirteen clinically well-characterized SS blood samples were included in the study. Diagnoses were established according to the WHO-EORTC classification for cutaneous lymphomas. 17 Clinical information of patients and samples are summarized in Table 1 and in Supplementary Table. The amount of tumor cells in each sample was estimated on peripheral blood parameters, atypical lymphocytes and staining with the corresponding Vb specific antibody and subsequent flow cytometry when applicable. The use of human material was approved by the Local Ethics Committee of the Charité (Berlin, Germany), and performed in accordance with the Declaration of Helsinki.
Cell lines, cell culture, viral vector production and transfection
The T-cell line Jurkat (acute T-cell leukemia-derived) and three CTCL cell lines HuT-78, 18 MyLa 19 and SeAx 20 were cultured in RPMI-1640 growth medium supplemented with 10% fetal calf serum, non-essential amino acids (MEM-NEA, Invitrogen, Carlsbad, CA, USA) and 1% sodium pyruvate at 37 1C and 5% CO 2 . SeAx cells received in addition 100 U/ml IL-2 (Peprotech, Rocky Hill, NJ, USA).
The virus-producing HEK293GP cell line (Clontech, Heidelberg, Germany) was cultured in Dulbecco's modified Eagle's medium (Invitrogen), supplemented with 10% fetal calf serum and non-essential amino acids at 37 1C and 5% CO 2 .
For virus production, HEK293GP cells were transfected with pMD2.G and pMIGR-A20, pMIGR (negative control) plasmids by calcium phosphate transfection. Target cells (SeAx) were transduced twice in 12 h intervals using viral supernatant supplemented with 4 mg/ml polybrene. The efficiency (GFP expression) was proven by flow cytometry 48-72 h after the last transduction. For knockdown experiments, 5 Â 10 6 human T cells were washed and resuspended in a total volume of 100 ml V-solution (Lonza, Basel, Switzerland). Cells were electroporated using a nucleofector II electroporation system (Lonza). Transfected cells were transferred to 24-well plates containing 1 ml pre-warmed growth medium.
Activation of human T cells
Human peripheral blood T cells were isolated from healthy donors by magnetic beads depleting CD3-negative cells and activated using a human T-cell activation/expansion kit (Miltenyi, Bergisch Gladbach, Germany). T cells were expanded in RPMI-1640 at a concentration of 5 Â 10 6 per ml, and after 3 days IL-2 was added (0.2 mg/ml) (PeproTech).
Enrichment of primary SS tumor cells from peripheral blood mononuclear cells
Peripheral blood mononuclear cells were isolated from whole blood or leukapheresis samples by density gradient centrifugation using Ficoll-Paque-Plus (GE Healthcare, Mü nchen, Germany). For enrichment of tumor cells, samples with an amount of greater than 90% of tumor cells within the CD4 positive cells were sorted with anti-CD4 microbeads (Miltenyi) according to the manufacture's recommendations.
Fine tiling CGH
A custom designed high-density fine-tiling array of 385 000 oligonucleotides, 40-60 bp in length, was prepared using the Maskless Array Synthesizer (MAS) technology (NimbleGen Systems; Reykjavik, Iceland). This array covering 24 Mb of genomic regions was selected using the Human Genome Browser hg18 assembly (University of California, Santa Cruz, CA, USA). Among others, the array included the A20 locus located on chromosome 6. After normalization with the reference DNA (healthy donor DNA from blood, Promega, Madison, USA) the mean fluorescence was analyzed using the SignalMap software (NimbleGen).
Sequence analysis of A20
Genomic DNA was isolated from peripheral blood mononuclear cells using Gentra Puregene Cell Kit (Qiagen, Hilden, Germany). All nine exons were amplified using Advantage GC Genomic LA Polymerase (Clontech) and sequenced by 3730XL/ 3130XL Genetic Analyzer (LGC Genomics, Berlin, Germany). Primer sequences used for amplification and sequencing are provided in Supplementary Materials and Methods.
Analysis of DNA methylation
Primer pairs surrounding CpG islands within the A20 promoter were designed using Primer3 online tool (Steve Rozen, Helen J Skaletsky (1998) Primer3). Genomic DNA was subjected to a bisulfate treatment using the CpGenome DNA Modification Kit (Chemicon International, Billerica. MA, USA) followed by PCR Cases with A20 deletion are marked in bold. Genomic DNA was checked by array-comparative genomic hybridization for genetic aberrations. Analysis of chromosome region 6q23 showed in 6/13 samples a deletion of A20. None of the tested patient samples showed mutations in the A20 coding sequence (exons 2-9) or mutations/methylations in the promotor region of A20.
TNFAIP3 is frequently deleted in Sézary syndrome FCM Braun et al amplification and sequencing (LGC Genomics). Genomic DNA from cells expressing A20 was used as a non-methylated control. Methylated DNA from Jurkat cells served as a positive control. Sequencing results were checked for the presence of cytosine or thymidine peaks within the A20-preceding CpGs. Vectors and siRNAs A20 was amplified from pCR-TOPO-Blunt II-TOPO A20 (OriGene, Rockville, MD) using the primers TNFAIP3-fo (5 0 -CT GGGACCATGGCACAACTC-3 0 ), TNFAIP3-re (5 0 -CGGAAGGTT CCATGGGATTC-3 0 ) and cloned into the retroviral vector pMIGR. The siRNA oligonucleotides for knockdown of A20 were provided by Ambion (Ambion, Applied Biosystems, Austin, TX, USA): s14259 (sense:
RNA extraction and quantitative RT-PCR
The siRNA with no specificity for any human gene with corresponding GC content was used as a negative control.
Viability and proliferation assays
Cell vitality was evaluated using Annexin-V-APC/-AAD staining kit (Pharmingen, San Diego, CA, USA) followed by FACS analysis. Cell cycle status was measured by propidium iodide/ RNase staining. To assess the fraction of cells undergoing DNA replication, the BrdU incorporation assay was applied (Pharmingen). The results of all measurements were obtained by FACS analysis and calculated using WinMDI 2.9 software (Windows Multiple Document Interface for Flow Cytometry).
Results and discussion
Frequent deletion of A20 in SS
The recurrent deregulation of the NF-kB pathway accompanied by high frequency of 6q23 deletions reported in a number of lymphoid malignancies provoked us to analyze this chromosomal region in SS. We performed fine tiling CGH analysis using genomic DNA isolated from blood samples of 13 SS patients with high tumor cell content and two SS-derived cell lines: SeAx 
and HuT-78. Biallelic deletions of the A20-encoding regions on chromosome 6 were detected in three and monoallelic deletions in three other patient samples (Figure 1a) . The A20 status of the clinical samples is summarized in Table 1 . CGH analysis of two SS-derived cell lines revealed no alterations in the cell line HuT-78, whereas the cell line SeAx showed a biallelic A20 deletion (Figure 1a) , accompanied by lack of mRNA and protein expression (Figure 2a) . No changes in copy number, methylation status or mutations were seen in HuT-78 or in two other T-cell lines Jurkat and MyLa, used as reference (not shown). Unlike A20-depleted SeAx, these three T-cell lines expressed A20 (Figure 2a) . The high frequency of genetic losses (6/13) indicated that depletion or inactivation of the A20 gene could represent a relevant step in SS development. A20 inactivation has been recently reported in B-cell lymphomas, thus suggesting A20 as a crucial tumor suppressor in these diseases. Frequent deletions were described in mucosa-associated lymphoid tissue (MALT) lymphoma, primary mediastinal B-cell lymphoma, marginal zone lymphoma 21 and Hodgkins lymphoma. So far, A20 deletions have been described only as rare events in T-cell neoplasms, and were reported in 14% of the chronic form of adult T-cell leukemia/lymphoma upon cytogenetic analysis. 22 Here, for the first time we report A20 deletions in a high percentage of cases in a T-cell-derived disease.
To verify whether the genomic loss of A20 was also reflected by loss of A20 expression, we analyzed mRNA expression in enriched tumor cells (490% purity) from one SS patient with biallelic deletions, two with monoallelic deletions and four without A20 deletion (Figure 2b ). In the biallelic deleted sample (308) no A20 expression was detected whereas in samples with monoallelic deletion and without deletion the expression varied markedly. For selected samples we also analyzed A20 expression on the protein level and as A20 is an inducible gene, we analyzed non-stimulated and PMA/Ionomycin stimulated cells. The treatment resulted in strong induction of A20 protein in healthy control samples (Figure 2c) . Interestingly, the patient sample carrying both alleles (313) showed strong A20 expression already under non-stimulating conditions. This result might be due to the positive selection of tumor samples, which may lead to A20 induction. In contrast, A20 protein expression in patient samples with monoallelic A20 deletion was weak (247) or, despite high mRNA level, even under stimulating conditions undetectable c(312), indicating further mechanisms for A20 inactivation beyond its genetic loss and transcriptional control. Apart from inefficient translation, reduced stability could explain the observed low A20 protein. As shown recently T-cell receptor stimulation causes rapid A20 cleavage initiated by the paracaspase activity of MALT1 protein followed by the proteasomal degradation. 23 As expected, no A20 signal was detected in the sample with biallelic A20 loss (308).
In B-cell lymphomas without A20 deletion inactivating mutations and promoter methylations were found. 5, 22, 24 Genome-wide analysis of genetic lesions in 238 cases confirmed the high prevalence of A20 inactivation. 24 This prompted us to sequence the exons and exon-intron borders of the non-deleted alleles. In contrast to other A20-deficient malignancies, in which mutations are the most frequent mechanism of A20 inactivation, no such alterations were detected in our collection of SS samples. Moreover, neither mutations in the promoter nor changes in its methylation pattern were found.
A20 reconstitution slows down cell cycle progression in the A20-negative cell line SeAx
To verify the possible tumor suppressive properties of A20 in SS, we re-expressed the gene in the SS cell line SeAx with a biallelic A20 deletion (Figure 1a) . Using a retroviral vector system, A20 was re-expressed in B70% of cells (Figure 3a) resulting in high TNFAIP3 is frequently deleted in Sézary syndrome FCM Braun et al protein levels (Figure 3b ). Unlike other A20-mutated or deficient lymphomas, no signs of cellular toxicity were detected in SeAx cells after A20 reconstitution, as determined by Annexin V/ 7-AAD staining and flow cytometry (Figure 3c) . Similarly, no enhanced apoptotic rates were seen as determined by quantification of sub-G1 cell populations (data not shown). However, as compared with mock-transduced cells, the growth of A20-transduced cells was significantly reduced. Thus, cell cycle profiling revealed a higher percentage of A20-transduced cells at G0/G1 phase (Table 2) , and in a BrdU-incorporation assays, A20-reconstituted SeAx cells showed a markedly lower BrdU content in genomic DNA than control cells (Figure 3d ). These data confirmed a reduced proliferative capacity and are in line with the tumor-suppressive potential of A20. Reconstitution of A20 in the A20-negative SS cell line SeAx resulted in markedly delayed cell cycle entry and progression, which further supported the contribution of A20 loss to cell growth in SS. Interestingly, unlike in B-cell-derived A20-negative cell lines, no influence on cellular survival was observed upon A20 reconstitution in SeAx. This, however, may reflect the apoptosis resistance resulting from acquired secondary genetic aberrations, which is a common phenomenon observed in cell lines derived from different tumors.
A20 knockdown in normal T cells enhances activation-induced proliferation
To further prove a tumor-suppressive activity of A20, we analyzed the effects of A20 depletion in purified normal T cells The Sé zary cell line SeAx was transduced with a retroviral vector encoding A20 (MIGR-A20) or the empty vector MIGR as a negative control. The mean percentage of cells at G0/G1, S and G2/M ( ± s.d.) were calculated from five independent experiments.
TNFAIP3 is frequently deleted in Sézary syndrome FCM Braun et al from healthy donors. These cells showed constitutive A20 mRNA expression. A pool of two different siRNAs targeting A20 (s14259, s14260) was proven effective in depleting A20 mRNA in resting T cells (Figure 4a ). However, there were no measurable biological consequences of A20 knockdown in normal T cells regarding cell vitality, cell number and cell cycle status (not shown). T cells, stimulated by a treatment mimicking TCR activation, showed meaningful decrease of A20 mRNA and protein upon siRNA treatment (Figure 4b ). Contrary to resting cells, activated T cells showed a significant increase in their replication activity in response to A20 depletion. This was manifested by reduced G0/G1 and increased S phase fractions as measured by DNA staining (Table 3) . Furthermore, despite relatively high differences between the donors, the BrdU incorporation assay showed evidently more BrdU-labeled cells after A20 knockdown (Figure 4c) . A clear transcriptional induction of various NF-kB target genes in A20 knockdowned T cells confirmed the role of A20 in regulating TCR-triggered NF-kB activation (Figure 4d ). Taken together, we observed significantly accelerated proliferation following CD3/CD28 stimulation. This suggests that even haplo-insufficiency of A20 may increase the proliferative potential of activated T cells and contribute to uncontrolled cell growth. Our data suggest that loss of A20 expression in T cells may lead to enhanced NF-kB activity, increased proliferation and as a consequence may contribute to malignant transformation.
As shown in a knockout mouse model, loss of A20 results in a constitutively active IKK complex and as a consequence constitutive NF-kB activation. 25 More recently, studies performed in lymphoid cells revealed the vital role of A20 in signal transduction from B-and T-cell receptors to NF-kB. In this cellular context, A20 was identified as a negative regulator of the NF-kB pathway perturbing the association of CARMA1/ BCL10/MALT1 complex with the IKK regulatory subunit IKKg/ NEMO, which represents the crucial linkage between B-and T-cell receptors and NF-kB. When overexpressed in a T cell line, A20 inhibited the PKC-driven NF-kB activation. 26 Its depletion in contrast enhanced the inducible production of IL-2 upon TCR-activation mimicking treatment. 27 Further, the deubiquitination activity of A20 was shown to be required for postinductive termination of IKK activity, regulation of the strength and duration of the IKK/NF-kB response triggered by TCR signaling. Moreover, removal of A20 abolished the need of CD28 costimulation to obtain a strong NF-kB activation. 23 All these findings strongly indicate the oncogenic properties of A20 loss, which leads to inappropriate or excessive NF-kB signaling and as a consequence might contribute to T-cell transformation.
We here show for the first time frequent deletion of A20 in SS samples. This finding is very well in line with the known constitutive NF-kB activation in SS. We further show, that A20 expression is altered in SS samples without A20 deletion, indicative for other mechanisms leading to deregulation. The pathways involved and molecules affected remain to be determined. Table 3 Cell cycle status of CD3+ T cells after A20 knockdown 
